ATE223967T1 - Druckvermittelte, intrazellulaere verabreichung von molekuelen oder mikropartikeln - Google Patents

Druckvermittelte, intrazellulaere verabreichung von molekuelen oder mikropartikeln

Info

Publication number
ATE223967T1
ATE223967T1 AT97948268T AT97948268T ATE223967T1 AT E223967 T1 ATE223967 T1 AT E223967T1 AT 97948268 T AT97948268 T AT 97948268T AT 97948268 T AT97948268 T AT 97948268T AT E223967 T1 ATE223967 T1 AT E223967T1
Authority
AT
Austria
Prior art keywords
cell
microparticles
mediated
molecules
pressure
Prior art date
Application number
AT97948268T
Other languages
English (en)
Inventor
Micheal J Mann
Victor J Dzau
Gary H Gibbons
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of ATE223967T1 publication Critical patent/ATE223967T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
    • A61M5/1452—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by means of pistons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
    • C12M3/04—Tissue, human, animal or plant cell, or virus culture apparatus with means providing thin layers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00—Constructional details, e.g. recesses, hinges
    • C12M23/02—Form or structure of the vessel
    • C12M23/14—Bags
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
    • C12M35/04—Mechanical means, e.g. sonic waves, stretching forces, pressure or shear stimuli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/40—Means for regulation, monitoring, measurement or control, e.g. flow regulation of pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M2025/1043—Balloon catheters with special features or adapted for special applications
    • A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M2025/1043—Balloon catheters with special features or adapted for special applications
    • A61M2025/1052—Balloon catheters with special features or adapted for special applications for temporarily occluding a vessel for isolating a sector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M25/1011—Multiple balloon catheters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Sustainable Development (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Cell Biology (AREA)
  • Medical Informatics (AREA)
  • Clinical Laboratory Science (AREA)
  • Dermatology (AREA)
  • Mechanical Engineering (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
AT97948268T 1996-11-07 1997-11-07 Druckvermittelte, intrazellulaere verabreichung von molekuelen oder mikropartikeln ATE223967T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/745,023 US5922687A (en) 1995-05-04 1996-11-07 Intracellular delivery of nucleic acids using pressure
PCT/US1997/020696 WO1998020109A1 (en) 1996-11-07 1997-11-07 Pressure-mediated intracellular delivery of molecules or microparticles

Publications (1)

Publication Number Publication Date
ATE223967T1 true ATE223967T1 (de) 2002-09-15

Family

ID=24994918

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97948268T ATE223967T1 (de) 1996-11-07 1997-11-07 Druckvermittelte, intrazellulaere verabreichung von molekuelen oder mikropartikeln

Country Status (15)

Country Link
US (1) US5922687A (de)
EP (2) EP0944715B1 (de)
JP (3) JP2001505419A (de)
KR (1) KR100449330B1 (de)
CN (1) CN1109749C (de)
AT (1) ATE223967T1 (de)
AU (1) AU736298B2 (de)
BR (1) BR9713334A (de)
CA (1) CA2271244C (de)
DE (1) DE69715449T2 (de)
DK (1) DK0944715T3 (de)
ES (1) ES2183221T3 (de)
IL (1) IL129808A (de)
PT (1) PT944715E (de)
WO (1) WO1998020109A1 (de)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803782B2 (en) * 2003-05-28 2010-09-28 Roche Madison Inc. Intravenous delivery of polynucleotides to cells in mammalian limb
US6627616B2 (en) * 1995-12-13 2003-09-30 Mirus Corporation Intravascular delivery of non-viral nucleic acid
US7507722B1 (en) 1999-11-05 2009-03-24 Roche Madison Inc. Intravascular delivery of nucleic acid
US20040259828A1 (en) * 1995-12-13 2004-12-23 Wolff Jon A. Intravascular delivery of non-viral nucleic acid
US6379966B2 (en) * 1999-02-26 2002-04-30 Mirus Corporation Intravascular delivery of non-viral nucleic acid
US20020001574A1 (en) * 1995-12-13 2002-01-03 Jon A. Woiff Process of delivering a polynucleotide to a muscle cell via the vascular system
US6676626B1 (en) 1998-05-01 2004-01-13 Ekos Corporation Ultrasound assembly with increased efficacy
US6582392B1 (en) 1998-05-01 2003-06-24 Ekos Corporation Ultrasound assembly for use with a catheter
US7435723B2 (en) * 1997-11-21 2008-10-14 Mirus Bio Corporation Process for delivery of polynucleotides to the prostate
US6699231B1 (en) 1997-12-31 2004-03-02 Heartport, Inc. Methods and apparatus for perfusion of isolated tissue structure
US6722370B1 (en) * 1998-07-17 2004-04-20 Corgentech, Inc. Delivery of a composition to the liver by utilizing the portal vein
WO2000015285A1 (en) * 1998-09-14 2000-03-23 Mirus Corporation A process for delivering nucleic acids to cardiac tissue
WO2000050617A1 (en) * 1999-02-26 2000-08-31 Mirus Corporation Intravascular delivery of non-viral nucleic acid
CA2374610A1 (en) * 1999-06-28 2001-01-04 Jordan J. N. Tang Catalytically active recombinant memapsin and methods of use thereof
DE60031442T2 (de) 1999-11-05 2007-03-29 Mirus Bio Corp., Madison Intravaskuläre nukleinsäurezuführung
US7642248B2 (en) * 1999-11-05 2010-01-05 Roche Madison Inc Devices and processes for distribution of genetic material to mammalian limb
US7214369B2 (en) * 2003-05-05 2007-05-08 Mirus Bio Corporation Devices and processes for distribution of genetic material to mammalian limb
EP1230268B1 (de) 1999-11-18 2009-10-14 Pharmexa Inc. Heteroklitische analoga von klasse-i epitopen
US20040072785A1 (en) * 1999-11-23 2004-04-15 Wolff Jon A. Intravascular delivery of non-viral nucleic acid
US6346098B1 (en) 2000-03-07 2002-02-12 The Board Of Trustees Of The Leland Stanford Junior University Methods and kits for locally administering an active agent to an interstitial space of a host
US7094408B2 (en) * 2000-04-28 2006-08-22 The United States Of America As Represented By The Department Of Health And Human Services Immunogenicity using a combination of DNA and vaccinia virus vector vaccines
DK1299727T3 (da) 2000-07-12 2009-06-15 Agensys Inc Hidtil ukendt tumorantigen, der er egnet til diagnosticering og behandling af blære-, ovarie-, lunge-, og nyrecancertyper
AU2001280789A1 (en) * 2000-07-25 2002-02-05 The Board Of Trustees Of The Leland Stanford Junior University Non-viral linear dna vectors and methods for using the same
CA2705366A1 (en) 2000-08-28 2002-03-07 Agensys, Inc. Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
CA2425648A1 (en) 2000-10-19 2002-04-19 Epimmune Inc. Hla class i and ii binding peptides and their uses
WO2002066611A2 (en) * 2001-02-16 2002-08-29 The Board Of Trustees Of The Leland Stanford Junior University Minimal plasmid vectors that provide for persistent and high level gene expression and methods for using the same
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
DK2280070T3 (en) * 2001-07-23 2015-08-24 Univ Leland Stanford Junior Methods and compositions for use in RNAi-mediated inhibition of gene expression in mammals
US10590418B2 (en) * 2001-07-23 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for RNAi mediated inhibition of gene expression in mammals
EP2287186B1 (de) 2001-09-06 2014-12-31 Agensys, Inc. Nucleinsäure und entsprechendes Protein, STEAP-1, bei der Behandlung und zum Nachweis von Krebs
EP1721977A3 (de) 2001-09-17 2008-10-15 PDL BioPharma, Inc. Verfahren zur Krebsdiagnose, Zusammensetzungen und Screening-verfahren für Krebsmodulatoren
US7220239B2 (en) 2001-12-03 2007-05-22 Ekos Corporation Catheter with multiple ultrasound radiating members
US7141044B2 (en) * 2001-12-11 2006-11-28 Ekos Corporation Alternate site gene therapy
DE10211589A1 (de) * 2002-03-15 2003-10-02 Steffen-Sebastian Bolz In vitro-Transfektion und Langzeitkultivierung von isolierten Organen
US8226629B1 (en) 2002-04-01 2012-07-24 Ekos Corporation Ultrasonic catheter power control
US20030204167A1 (en) * 2002-04-24 2003-10-30 Johnson Lanny L. Device for delivering liquid medications, nutrients or gases to local tissue
WO2004041997A2 (en) * 2002-05-01 2004-05-21 National Institutes Of Health Immunotherapy regimens in hiv-infected patients
US20030228691A1 (en) * 2002-05-17 2003-12-11 Lewis David L. Processes for inhibiting gene expression using polynucleotides
AU2003274463B2 (en) 2002-06-10 2009-10-29 University Of Rochester Gene differentially expressed in breast and bladder cancer and encoded polypeptides
WO2004011060A2 (en) * 2002-07-26 2004-02-05 Mirus Corporation Delivery of molecules and complexes to mammalian cells in vivo
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
WO2004020605A2 (en) * 2002-08-29 2004-03-11 The Board Of Trustees Of The Leland Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
US6921371B2 (en) 2002-10-14 2005-07-26 Ekos Corporation Ultrasound radiating members for catheter
EP1565200A4 (de) 2002-11-27 2009-06-24 Agensys Inc NUKLEINSûURE ENTSPRECHENDES PROTEIN 24P4C12 ZUR BEHANDLUNG UND ERKENNUNG VON KREBS
EP1903056A3 (de) 2002-12-10 2008-05-07 Idm Pharma, Inc. HLA-A1, -A2, -A3, -A24, -B7 and -B44 bindende Peptide die Tumorassoziiert-Antigen Epitopen enthalten, und Zusammensetzungen davon
US7781415B2 (en) * 2003-02-07 2010-08-24 Roche Madison Inc. Process for delivering sirna to cardiac muscle tissue
JP2007524361A (ja) 2003-02-10 2007-08-30 アジェンシス， インコーポレイテッド 膀胱癌及びその他の癌の治療及び検出に有用な名称１５８ｐ１ｄ７の核酸及び対応タンパク質
WO2004105681A2 (en) * 2003-04-28 2004-12-09 Innogenetics N.V. Cd4+ human papillomavirus (hpv) epitopes
CA2526274C (en) 2003-05-30 2015-12-01 Agensys, Inc. Prostate stem cell antigen (psca) variants and subsequences thereof
CA2536735C (en) * 2003-09-05 2013-01-22 Genencor International, Inc. Methods for determining cd8+ t-cell epitopes
WO2005035547A2 (en) * 2003-10-06 2005-04-21 Corgentech, Inc. E2f oligonucleotide decoy molecules
EP1709175A2 (de) * 2003-12-03 2006-10-11 Corgentech, Inc. Hif-oligonukleotid-ködermoleküle
US20050191344A1 (en) * 2004-01-15 2005-09-01 Samuel Zalipsky Liposome composition for delivery of therapeutic agents
GB0406728D0 (en) * 2004-03-25 2004-04-28 Hydrodynamic Gene Delivery Ltd Gene therapy
ES2361458T5 (es) 2004-05-04 2016-04-20 The Board Of Trustees Of The Leland Stanford Junior University Procedimientos y composiciones para reducir las cantidades de genoma vírico de VHC en una célula diana
WO2005112620A2 (en) * 2004-05-18 2005-12-01 Massachusetts Institute Of Technology A cre-lox based method for conditional rna interference
NZ551627A (en) 2004-05-28 2010-02-26 Agensys Inc Antibodies and related molecules that bind to PSCA proteins
US7482158B2 (en) * 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
EP1799835A4 (de) * 2004-08-23 2009-05-13 Hong Bock Lee Verfahren zum gentransfer in die organellen von zellen: direkter gentransfer in mitochondrien
US20070036740A1 (en) * 2004-10-06 2007-02-15 Reed Kenneth C Modulation of hair growth
CA2583826A1 (en) * 2004-10-22 2006-05-04 Benitec, Inc. Therapeutic rnai agents for treating psoriasis
US20060115462A1 (en) * 2004-12-01 2006-06-01 Vladimir Subbotin Direct DNA delivery to bone cells
US20090023671A1 (en) * 2005-01-06 2009-01-22 Brashears Sarah J Rnai Agents for Maintenance of Stem Cells
ES2364670T3 (es) 2005-02-25 2011-09-12 Oncotherapy Science, Inc. Vacunas de péptidos para cánceres de pulmón que expresan polipéptidos ttk.
DK2095822T3 (da) 2005-02-28 2014-01-13 Oncotherapy Science Inc Epitoppeptider afledt af karendothelvækstfaktorreceptor-1 samt vacciner indeholdende disse peptider
RU2413735C2 (ru) 2005-03-31 2011-03-10 Эдженсис, Инк. Антитела и родственные молекулы, связывающиеся с белками 161p2f10b
US20060292159A1 (en) * 2005-06-08 2006-12-28 Ranscht Barbara E Methods for the inhibition of neovascularization and cancer metastasis
HUE027330T2 (en) 2005-07-27 2016-09-28 Oncotherapy Science Inc Colon cancer related gene tom34
CA2618508A1 (en) * 2005-08-10 2007-02-22 Oklahoma Medical Research Foundation Truncated memapsin 2 for use for treating alzheimer's disease
US20070143195A1 (en) * 2005-12-15 2007-06-21 Bell Ryan B Systems and methods for evaluating terms of a deal to purchase a vehicle
US20070173470A1 (en) * 2006-01-23 2007-07-26 Chi-Hung Lin Methods for delivering extracellular target into cells
KR101543622B1 (ko) 2006-10-17 2015-08-11 온코세라피 사이언스 가부시키가이샤 Ｍｐｈｏｓｐｈ1 또는 ｄｅｐｄｃ1 폴리펩티드를 발현하는 암에 대한 펩티드 백신
US10182833B2 (en) 2007-01-08 2019-01-22 Ekos Corporation Power parameters for ultrasonic catheter
TWI596109B (zh) 2007-02-21 2017-08-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
WO2008112226A2 (en) * 2007-03-13 2008-09-18 Massachusetts Institute Of Technology Cre-lox based gene knockdown constructs and methods of use thereof
TW201425333A (zh) 2007-04-11 2014-07-01 Oncotherapy Science Inc 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗
DK2476689T3 (en) 2007-05-10 2016-01-18 Agilent Technologies Inc Thiocarbonbeskyttende groups for RNA synthesis
ES2471118T3 (es) 2007-06-22 2014-06-25 Ekos Corporation Método y aparato para el tratamiento de hemorragias intracraneales
EP2612867A1 (de) 2007-11-01 2013-07-10 Perseid Therapeutics LLC Immunsuppressive Polypeptide und Nucleinsäuren
JP2011502484A (ja) 2007-11-01 2011-01-27 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Ｈｌａ−ｄｒ結合性ペプチドおよびそれらの使用
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US20110129499A1 (en) 2008-05-19 2011-06-02 Paulo Maciag Dual delivery system for heterologous antigens
WO2009152618A1 (en) 2008-06-17 2009-12-23 The Governing Council Of The University Of Toronto Device for investigation of a flow conduit
US8945885B2 (en) 2008-07-03 2015-02-03 The Board Of Trustees Of The Leland Stanford Junior University Minicircle DNA vector preparations and methods of making and using the same
US8236548B2 (en) * 2008-07-03 2012-08-07 The Board Of Trustees Of The Leland Stanford Junior University Minicircle DNA vector preparations and methods of making and using the same
WO2010023877A1 (en) 2008-08-27 2010-03-04 Oncotherapy Science, Inc. Prmt1 for target genes of cancer therapy and diagnosis
JP2012506858A (ja) * 2008-10-23 2012-03-22 インターベット インターナショナル ベー． フェー． Ｌａｗｓｏｎｉａｉｎｔｒａｃｅｌｌｕｌａｒｉｓワクチン
CN102292069B (zh) 2008-11-26 2014-07-30 中外制药株式会社 囊泡制剂
EP2368989A4 (de) 2008-11-26 2012-09-26 Chugai Pharmaceutical Co Ltd Oligoribonukleotid- bzw. peptidnukleinsäure zur hemmung der aktivität des hepatitis-c-virus
TWI539160B (zh) 2008-12-05 2016-06-21 腫瘤療法 科學股份有限公司 Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
US9017991B2 (en) * 2009-03-13 2015-04-28 Tufts University Methods tip assemblies and kits for introducing material into cells
WO2010105135A1 (en) 2009-03-13 2010-09-16 Tufts University Methods, apparatuses, and kits for introducing genetic material into living cells
ES2617434T3 (es) 2009-03-18 2017-06-19 Oncotherapy Science, Inc. Péptidos NEIL3 y vacunas que incluyen los mismos
TWI507204B (zh) 2009-05-26 2015-11-11 Oncotherapy Science Inc Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
TW201136604A (en) 2009-12-14 2011-11-01 Oncotherapy Science Inc TMEM22 peptides and vaccines including the same
US20130052221A1 (en) 2010-02-26 2013-02-28 The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services Dna-protein vaccination protocols
CN105601727B (zh) 2010-03-11 2020-01-10 肿瘤疗法科学股份有限公司 Hjurp肽及包含它们的疫苗
US11020444B2 (en) * 2010-04-23 2021-06-01 Scicotec Gmbh Transluminal delivery of viruses for treatment of diseased tissue
WO2012138377A2 (en) 2010-10-01 2012-10-11 Trustees Of The University Of Pennsylvania The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
JP5564730B2 (ja) 2011-08-12 2014-08-06 オンコセラピー・サイエンス株式会社 Ｍｐｈｏｓｐｈ１ペプチドおよびそれを含むワクチン
CN104066746B (zh) 2011-10-28 2017-12-05 肿瘤疗法科学股份有限公司 Topk肽及包含它们的疫苗
WO2013138337A1 (en) 2012-03-12 2013-09-19 Advaxis Suppressor cell function inhibition following listeria vaccine treatment
WO2014010232A1 (en) 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Ly6k epitope peptides for th1 cells and vaccines containing the same
JP6259983B2 (ja) 2012-07-10 2018-01-17 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のＫＩＦ２０Ａエピトープペプチドおよびこれを含有するワクチン
CA2873155C (en) 2012-09-11 2022-07-26 Oncotherapy Science, Inc. Ube2t peptides and vaccines containing the same
CA2895791A1 (en) 2013-01-25 2014-07-31 Xcell Biosciences, Inc. Methods, compositions, kits, and systems for selective enrichment of target cells
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
CN105452471A (zh) 2013-03-15 2016-03-30 加利福尼亚大学董事会 使用光热平台向活细胞中的高通量运输物递送
CA2908042C (en) 2013-03-27 2023-01-31 Immunovaccine Technologies Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer
US10472651B2 (en) 2014-03-28 2019-11-12 The Regents Of The University Of California Efficient delivery of large cargos into cells on a porous substrate
US10760040B1 (en) 2014-07-03 2020-09-01 NanoCav, LLC Mechanical transfection devices and methods
US10081816B1 (en) * 2014-07-03 2018-09-25 Nant Holdings Ip, Llc Mechanical transfection devices and methods
EP3981416B1 (de) 2014-08-04 2024-03-20 OncoTherapy Science, Inc. Koc1-abgeleitetes peptid und impfstoff damit
JP6700512B2 (ja) 2014-08-04 2020-05-27 オンコセラピー・サイエンス株式会社 Ｃｄｃａ１由来ペプチドおよびそれを含むワクチン
SG11201700838VA (en) 2014-08-04 2017-03-30 Oncotherapy Science Inc Urlc10-derived peptide and vaccine containing same
EP3242883A4 (de) 2015-01-06 2018-10-17 ImmunoVaccine Technologies Inc. Lipid-a-mimetika, verfahren zur herstellung und verwendungen davon
ES2959642T3 (es) 2015-05-13 2024-02-27 The Us Secretary Of The Department Of Health And Human Services Metodos y composiciones para inducir una respuesta inmunitaria mediante construcciones con elementos conservados
EP3307388B1 (de) 2015-06-10 2022-06-22 Ekos Corporation Ultraschallkatheter
BR112018005581A2 (pt) 2015-10-08 2018-10-16 Oncotherapy Science, Inc. peptídeo derivado de foxm1 e vacina incluindo o mesmo
US20170369904A1 (en) * 2016-06-22 2017-12-28 Xcell Biosciences, Inc. Methods for increasing cell culture transfection efficiency and cellular reprogramming
US10533189B2 (en) * 2016-09-20 2020-01-14 The Chinese University Of Hong Kong Highly specific delivery of polynucleotides to the cell nucleus via compression
US11801364B2 (en) * 2017-06-30 2023-10-31 Avectas Limited Electrospray catheter
EP3802779A1 (de) * 2018-06-01 2021-04-14 Avectas Limited Plattform für zell-engineering
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
CN118139663A (zh) * 2021-06-24 2024-06-04 阿维塔斯有限公司 喷雾喷嘴
CN114736796A (zh) * 2021-12-13 2022-07-12 湖北嘉士医疗科技有限公司 一种旋转阀芯组合的核酸检测试剂盒
US20250065080A1 (en) * 2021-12-23 2025-02-27 Aldevron, Llc Devices and methods for hollow tissue electrotransfer
WO2025024923A1 (en) * 2023-07-28 2025-02-06 Henderson Jeffrey T Method, system and apparatus for the introduction of materials across lipid membranes using modifications in hydrostatic pressure
US20250327090A1 (en) * 2024-04-23 2025-10-23 TransCytos, LLC Devices and Methods for Transfection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5698531A (en) * 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5674192A (en) * 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
US5584803A (en) * 1991-07-16 1996-12-17 Heartport, Inc. System for cardiac procedures
US5766901A (en) * 1995-05-04 1998-06-16 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and method for delivering a nucleotide into cell nuclei

Also Published As

Publication number Publication date
EP1279412A2 (de) 2003-01-29
CA2271244A1 (en) 1998-05-14
DK0944715T3 (da) 2002-12-30
DE69715449D1 (de) 2002-10-17
CA2271244C (en) 2008-09-02
JP2008054681A (ja) 2008-03-13
US5922687A (en) 1999-07-13
DE69715449T2 (de) 2003-07-31
ES2183221T3 (es) 2003-03-16
EP1279412A3 (de) 2003-12-17
PT944715E (pt) 2003-01-31
IL129808A (en) 2004-06-20
CN1244213A (zh) 2000-02-09
KR100449330B1 (ko) 2004-09-18
JP2001505419A (ja) 2001-04-24
EP0944715B1 (de) 2002-09-11
EP0944715A4 (de) 1999-12-22
AU736298B2 (en) 2001-07-26
KR20000053164A (ko) 2000-08-25
BR9713334A (pt) 2000-05-09
WO1998020109A1 (en) 1998-05-14
IL129808A0 (en) 2000-02-29
HK1022711A1 (en) 2000-08-18
CN1109749C (zh) 2003-05-28
AU7002098A (en) 1998-05-29
JP2008237221A (ja) 2008-10-09
EP0944715A1 (de) 1999-09-29

Similar Documents

Publication Publication Date Title
ATE223967T1 (de) Druckvermittelte, intrazellulaere verabreichung von molekuelen oder mikropartikeln
RU94014623A (ru) Состав и способ отделения, разделения и концентрирования требуемых ионов из растворов
ATE250426T1 (de) Verwendung von verbindungen die an ein zytoplasmatischen dipeptidase binden zur potenzierung des immunantworts
NO931689D0 (no) Anordning for elektrokjemisk syntese for "in-line" og "off-line", bleking, oksidasjon og desinfeksjon av organiske sstoffer i vaesker.
KR920004281A (ko) 폐수처리 공정에서 고-액분리 및 농축방법
CA2004068A1 (en) Hair analysis method
Giffin The benefits and detriments of ability grouping and its effectiveness
Occulto Writing in the biology classroom
Welshans A comparison of science process skills of fourth grade students using alternative assessment
Wallace The efficacy of retaining students in the early primary grades
Hughes An analysis on the opinions of teachers toward homework
Jewell An analysis of teacher opinions and practice regarding the use of African American children's literature in the elementary classroom
Brown A quantitative analysis of the effectiveness of LOGO as an instructional aid for teaching mechanics in physics
Lyons An analysis of the attitudes of fifth grade social studies students toward the use of cooperative learning techniques
Abou Jaoude Plastic analysis of rigid frames using micro computer graphics
McMahon An analysis of teaching spelling by using high frequency words
Newhouse Handbook for the implementation of aesthetics in the Art I curriculum in Beavercreek High School
Long An investigation of self-chosen instructional strategies for the remediation of handwriting
Beck Split sessions and science achievement of intermediate students
Tobias Reading Trends
TW290665B (en) Information processing method of compressing or decompressing bit map font data and device thereof
Brown Developing strategies to encourage and improve parent participation in an early childhood program adapting the Reggio Emilia approach to early childhood education
Gerardi Learning centers in language arts and mathematics for first grade teachers
O'Connor An analysis of calculus students' attitudes toward cooperative learning
Hershey Using sustained silent reading to develop independent reading habits and attitudes in elementary students

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0944715

Country of ref document: EP

REN Ceased due to non-payment of the annual fee